North America Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Instruments, Reagents and Assays, Blood Culture Media, and Software), Technology [Molecular Diagnostics (Polymerase Chain Reaction, Peptide Nucl

North America Sepsis Diagnostics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product (Instruments, Reagents and Assays, Blood Culture Media, and Software), Technology [Molecular Diagnostics (Polymerase Chain Reaction, Peptide Nucleic Acid-Fluorescent in Situ Hybridization, Syndromic Panel-Based Testing, and Microarrays), Flow Cytometry, Microfluidics, Immunoassay, Biomarkers, and Microbiology], Method (Automated Diagnostics and Conventional Diagnostics), Test Type (Point-of-Care Tests and Laboratory Tests), Pathogen (Bacterial Sepsis, Fungal Sepsis, and Others), and End User (Hospitals, Pathology and Reference Laboratories, and Others)

The North America sepsis diagnostics market is expected to grow from US$ 279.06 million in 2021 to US$ 513.33 million by 2028. It is estimated to record a CAGR of 9.1% from 2021 to 2028.

High Incidence of Sepsis due to Increasing Nosocomial Infections Drives North America Sepsis Diagnostics Market

Infection is the root cause of sepsis. Sepsis mainly occurs in immunocompromised people, such as those taking chemotherapy, having a splenectomy, and suffering from AIDS and diabetes and other chronic illnesses. Among several types of infections, nosocomial infections are the primary cause of morbidity and mortality among hospitalized patients. According to the 2020 National and State Healthcare-Associated Infections Progress Report published by the Centers for Disease Control and Prevention (CDC) in 2021, the US recorded about 24%, 35%, and 15% increase in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, respectively, between 2019 and 2020. As per a report published by the Global Sepsis Alliance (GSA), nearly 26 million people develop sepsis every year, and ~8 million deaths are reported due to sepsis across the world. Thus, the rising bloodstream infections will increase the adoption of sepsis diagnostic products. Also, deaths are often a consequence of diarrheal diseases or lower respiratory infections. Most deaths can be prevented through early diagnosis and appropriate clinical management. Thus, the high incidence rate of sepsis is expected to boost the demand for sepsis diagnostic products, which would support the North America sepsis diagnostics market growth during the forecast period.

North America Sepsis Diagnostics Market Overview

The North America sepsis diagnostics market is segmented into the US, Canada, and Mexico. The US held the largest share of the North American sepsis diagnostics market in 2021. In North America, the increasing adoption of technological advancements in the field of sepsis diagnostics, high adoption of innovative sepsis diagnostic technologies among medical professionals, and increasing incidence of healthcare-associated infections (HAIs) have accelerated the growth of the North America sepsis diagnostics market.

North America Sepsis Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

North America Sepsis Diagnostics Market Segmentation

The North America sepsis diagnostics market is segmented on the basis of product, technology, method, test type, pathogen, end user, and country.

Based on product, the North America sepsis diagnostics market is segmented into instruments, reagents and assays, blood culture media, and software. The blood culture media segment held the largest market share in 2021.

Based on technology, the North America sepsis diagnostics market is segmented into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. The microbiology segment held the largest market share in 2021. The market for the molecular diagnostics segment is sub segmented into polymerase chain reaction, peptide nucleic acid-fluorescent in situ hybridization, syndromic panel-based testing, and microarrays.

Based on method, the North America sepsis diagnostics market is bifurcated into automated diagnostics and conventional diagnostics. The conventional diagnostics segment held a larger market share in 2021.

Based on test type, the North America sepsis diagnostics market is bifurcated into point-of-care tests and laboratory tests. The laboratory tests segment held a larger market share in 2021.

Based on pathogen, the North America sepsis diagnostics market is segmented into bacterial sepsis, fungal sepsis, and others. The bacterial sepsis segment held the largest market share in 2021.

Based on end user, the North America sepsis diagnostics market is segmented into hospitals, pathology and reference laboratories, and others. The hospitals segment held the largest market share in 2021.

Based on country, the North America sepsis diagnostics market is segmented into the US, Canada, and Mexico. The US dominated the market share in 2021.

Abbott; BD; bioMerieux SA; Danaher (Beckman Coulter); F. HOFFMANN-LA ROCHE LTD.; Immunexpress Inc.; Luminex Corporation; T2 Biosystems, Inc.; and THERMO FISHER SCIENTIFIC INC. are among the leading companies operating in the North America sepsis diagnostics market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North American sepsis diagnostics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in North American sepsis diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.